

Cediranib maleate with or without gefitinib in treating patients with recurrent or progressive glioblastoma

Submission date 27/05/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 27/05/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 20/01/2022	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/a-study-looking-cediranib-with-without-gefitinib-for-type-brain-tumour-glioblastoma-doric>

Contact information

Type(s)

Scientific

Contact name

Dr Fiona Dungey

Contact details

Cancer Research UK & UCL Cancer Trials Centre
90 Tottenham Court Road
London
United Kingdom
W1T 4TJ

Additional identifiers

Clinical Trials Information System (CTIS)

2010-021531-13

ClinicalTrials.gov (NCT)

NCT01310855

Protocol serial number

9563

Study information

Scientific Title

Multi-centre, randomised, double-blind phase II study comparing cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma (DORIC Trial)

Acronym

DORIC

Study objectives

This is a phase II, randomised, double-blind placebo-controlled study in patients with recurrent or progressive glioblastoma (WHO grade IV). Patients are to receive cediranib in combination with gefitinib or cediranib with placebo. The primary endpoint is Progression Free Survival.

Ethics approval required

Old ethics approval format

Ethics approval(s)

First MREC approval on 17/02/2011, ref:10/H0715/77

Study design

Randomised interventional trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Brain Tumour

Interventions

This is a randomised double blind multicentre phase II trial of daily cediranib +/- gefitinib for patients with recurrent/progression Glioblastoma. Patients will continue treatment until confirmed progression, patient decision or the development of unacceptable toxicity. Follow up for the trial is continuous unless the patient requests otherwise. A translational component will examine the roles of potential biomarkers and stratify the results based on known indicators of prognosis such as MGMT methylation and IDH 1 and 2. Doses: Cediranib 30mg daily, Gefitinib 500mg or matching placebo daily

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Cediranib, gefitinib

Primary outcome(s)

1. Progression free survival
2. Timepoint(s): throughout trial

Key secondary outcome(s)

1. Overall survival, timepoint(s): date of death
2. Overall survival rate at 12 months, timepoint(s): 12 months
3. Progression free survival at 6 months, timepoint(s): 6 months
4. Radiographic response rate, timepoint(s): at each MRI scan (6 weekly)
5. Safety and tolerability, timepoint(s): throughout trial
6. Steroid use, timepoint(s): throughout trial
7. Time to deterioration of neurological status or death, timepoint(s): throughout trial, death
8. Time to sustained increase in steroid dosage, timepoint(s): throughout trial

Completion date

24/11/2012

Eligibility

Key inclusion criteria

1. Provision of informed consent
2. Age ≥ 18 years
3. Life expectancy ≥ 12 weeks
4. Histological/cytological confirmation of glioblastoma (WHO grade IV)
5. Patients with measurable disease (contrast-enhancing tumour ≥ 10 mm by shortest diameter on 2 axial slices) by MRI imaging within 7 days prior to enrolment. (If patients have recently had a routine MRI scan, this should be assessed before deciding whether or not to screen the patient, and booking the screening/baseline MRI.)
6. Patients must have been on no steroids or a stable dose of steroids (dexamethasone) for at least 5 days before the baseline MRI
7. Patients must have completed standard first-line treatment for glioblastoma including surgery (with exception, if patient does not receive surgery as part of first-line treatment due to anatomical location, based on neurosurgeon's assessment), cranial radiotherapy and chemotherapy with concomitant temozolomide
 - 7.1. It is not essential that the entire Stupp regimen of 6 cycles of adjuvant temozolomide following chemoradiotherapy has been completed
 - 7.2. The last dose of temozolomide must be more than 28 days from enrolment
 - 7.3. Gliadel® wafers are permitted, as it is part of local treatment
 - 7.4. No other previous treatment for glioblastoma is permitted (other than steroids)
8. Patients must have a Karnofsky Performance Score of 70 or above
9. Patients must have a mini-mental status examination score of 15 or greater
10. Patients who require either oral anticoagulants (coumadin, warfarin) or low molecular weight heparin are eligible provided there is increased vigilance with respect to monitoring INR.
11. For inclusion in the genetic research, patients must fulfil the following criterion:
 - 11.1. Provision of informed consent for genetic research (separate consent required for tumour biopsy, blood sample, and post mortem donations)
 - 11.2. If a patient declines to participate in any of the genetic research, there will be no penalty or loss of benefit to the patient
 - 11.3. The patient will not be excluded from other aspects of the study described in this Clinical Study Protocol, so long as they consent to the main study

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

38

Key exclusion criteria

1. Patients on enzyme-inducing anti-epileptic drugs within 2 weeks prior to study enrolment
Note: Patients are eligible if they switched to non-enzyme inducing agents and discontinued enzyme-inducing agents for more than or equal to 2 weeks prior to randomisation
2. Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count $\leq 1.5 \times 10^9$ /L or platelet count $\leq 100 \times 10^9$ /L or requiring regular blood transfusions to maintain haemoglobin $>9\text{g/dL}$
3. Serum bilirubin $\geq 1.5 \times \text{ULRR}$ (except for patients with known documented cases of Gilberts Syndrome)
4. ALT or AST $\geq 5 \times \text{ULRR}$
5. Serum creatinine $>1.5 \times \text{ULRR}$ or a creatinine clearance of $\leq 50\text{mL/min}$ calculated by Cockcroft-Gault
6. Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein $<1.5\text{g}$ in a 24 hr period or UPC (Urine Protein: Creatinine) ratio <1.5
7. History of significant gastrointestinal impairment, as judged by the investigator, that would significantly affect the absorption of cediranib or gefitinib, including the ability to swallow the tablet whole
8. Patients with a history of poorly controlled hypertension with resting blood pressure $>150/100\text{mmHg}$ in the presence or absence of a stable regimen of anti-hypertensive therapy, or patients who are requiring maximal doses of calcium channel blockers to stabilise blood pressure
9. Any evidence of severe or uncontrolled diseases (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
10. Unresolved toxicity $>\text{CTC AE grade 1}$ from previous anti-cancer therapy (including radiotherapy) except alopecia (if applicable)
11. Mean QTc with Bazetts correction $>470\text{msec}$ in screening ECG or history of familial, long QT syndrome
12. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
13. Significant haemorrhage ($>30\text{mL}$ bleeding/episode in previous 3 months) or haemoptysis ($>5\text{mL}$ fresh blood in previous 4 weeks)
14. Recent (<14 days) major surgery or brain biopsy
15. Recent craniotomy (<28 days) prior to first dose, or a surgical incision that is not fully healed
16. Pregnant or breast-feeding women or women of childbearing potential with a positive pregnancy test prior to receiving study medication

17. Known hypersensitivity to cediranib, gefitinib or any of its excipients
18. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years, unless the patient has been disease free for 2 years and they have tissue diagnosis of the target lesion
19. Known infection with hepatitis B or C or HIV
20. Involvement in the planning and conduct of the study (applies to both UCL CTC, AstraZeneca staff and staff at the study site)
21. Past medical history of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease
22. Previous enrolment as part of the present study
23. Treatment with an investigational drug within 30 days prior to the first dose of cediranib /gefitinib
24. Other concomitant anti-cancer therapy except steroids (dexamethasone only)
25. Previous anti-angiogenesis (e.g. bevacizumab, sorafenib, sunitinib) therapy
26. Previous anti-EGFR treatments (e.g. cetuximab, panitumumab or small molecule tyrosine kinase inhibitors etc.) or downstream targets e.g. mTOR inhibitors
27. Patients with evidence of any intratumoural or peritumoural haemorrhage deemed significant by the treating physician
28. Patients who have received any form of cranial radiation within 3 months prior to study entry (excluding imaging)
29. Patients who have progressed within 3 months of completion of standard cranial radiation
30. Patients that have received radiosurgery or brachytherapy
31. Patients on >8mg/day dexamethasone or equivalent steroids on any day of the 2 weeks prior to randomisation

Date of first enrolment

24/05/2011

Date of final enrolment

08/08/2012

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Cancer Research UK & UCL Cancer Trials Centre

London

United Kingdom

W1T 4TJ

Sponsor information

Organisation

University College London (UK)

ROR

<https://ror.org/02jx3x895>

Funder(s)

Funder type

Industry

Funder Name

AstraZeneca (UK)

Alternative Name(s)

AstraZeneca PLC, Pearl Therapeutics, AZ

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	27/05/2016		Yes	No
Basic results			20/05/2019	No	No
HRA research summary			28/06/2023	No	No
Plain English results			20/01/2022	No	Yes